U.S. Markets closed
  • S&P 500

    3,901.36
    +0.57 (+0.01%)
     
  • Dow 30

    31,261.90
    +8.77 (+0.03%)
     
  • Nasdaq

    11,354.62
    -33.88 (-0.30%)
     
  • Russell 2000

    1,773.27
    -2.96 (-0.17%)
     
  • Crude Oil

    110.35
    +0.46 (+0.42%)
     
  • Gold

    1,845.10
    +3.90 (+0.21%)
     
  • Silver

    21.87
    -0.03 (-0.13%)
     
  • EUR/USD

    1.0562
    -0.0026 (-0.2429%)
     
  • 10-Yr Bond

    2.7870
    -0.0680 (-2.38%)
     
  • Vix

    29.43
    +0.08 (+0.27%)
     
  • GBP/USD

    1.2495
    +0.0020 (+0.1587%)
     
  • USD/JPY

    127.8500
    +0.0560 (+0.0438%)
     
  • BTC-USD

    29,232.74
    -908.02 (-3.01%)
     
  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     
  • FTSE 100

    7,389.98
    +87.24 (+1.19%)
     
  • Nikkei 225

    26,739.03
    +336.19 (+1.27%)
     

Cingulate completes $25M IPO, becomes KC area's newest public company

·1 min read
Cingulate completes $25M IPO, becomes KC area's newest public company
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

A Westwood company developing new pharmaceutical treatments raised roughly $25 million for the effort through an initial public stock offering on Friday. Cingulate Inc. sold more than 4.1 million shares, packaged with warrants, in its IPO. Cingulate is developing drugs using proprietary Precision Timed Release technology to address problems caused by frequency of dosing or declines in the drug level in patients between doses. The company has three drugs in its development pipeline — two for treatment of attention-deficit/hyperactivity disorder (ADHD) and one for anxiety.